Articles tagged with Oncology
A study of over 60,000 US patients with advanced breast cancer found average survival times increased by six to seven months since 2011. Researchers attribute the improvement to more effective treatments, wider diagnosis, and quality of care advancements.
A new case report describes the successful treatment of a 37-year-old woman with HER2-positive breast cancer that had spread to the membranes surrounding the brain and spinal cord. Trastuzumab deruxtecan, an antibody-drug conjugate, improved the patient's neurological symptoms and reduced cancer growth.
The ABC Global Decade Report 2015-2025 reveals significant advances in breast cancer care for some patients globally. However, persistent inequalities leave many behind. The report's findings drive the creation of the ABC Global Charter 2025-2035, aiming to improve equitable progress and transform care for everyone with ABC.
A study published in the Chinese Medical Journal identified GSTP1 as a key regulator that blocks JNK-driven ferroptosis, providing protection against DOX-induced cardiomyopathy. Overexpression of GSTP1 inhibited ferroptosis and improved DOX-induced heart injury.
A new editorial highlights the importance of primary care in preventing heart disease in breast cancer survivors. The study found that most women do not go on to develop serious cardiac disease, but those with higher-risk chemotherapy, older age, or multiple cardiovascular risk factors may benefit from closer monitoring.
The National Comprehensive Cancer Network (NCCN) has expanded access to cancer treatment in Sub-Saharan Africa with new international adaptations. The adaptations reflect significant progress in cancer care delivery, including increased access to imaging techniques and biomarker testing.
The DEFEND study aims to assess whether virtual exercise sessions can be successfully delivered to patients with cancer receiving chemotherapy. Researchers will evaluate the impact on physical function, fatigue, and disability.
Researchers at Mass General Brigham have developed a strategy to promote antitumor immunity by inducing cancer cells to produce an immune-activating molecule. This approach was shown to reduce tumor growth and improve survival in mouse models of aggressive melanoma, with potential applications beyond cancer therapies.
A rare case of a mucinous vulvar cyst was reported, which resembled a benign lipoma and caused lower abdominal and back pain. The cyst was surgically removed and confirmed to be non-malignant. The case underscores the importance of careful clinical examination in reproductive-age women presenting with vulvar masses.
A new study found that more than half of American adults misunderstand the link between alcohol consumption and cancer. Alcohol drinkers are particularly likely to believe drinking has no effect on cancer risk. Correcting these misbeliefs may strengthen adherence to U.S. Surgeon General’s guidelines for lowering cancer risk.
Ochsner MD Anderson Cancer Center has seven locations recertified for quality cancer care, demonstrating a commitment to comprehensive holistic care. The QOPI Certification Program recognizes these locations for meeting national standards and objectives.
Artificial intelligence is transforming cancer prevention, detection, and treatment by connecting technology with people. AI-driven public-health analytics, patient-doctor relationships, and diverse clinical research are crucial for delivering immediate benefit to patients, clinicians, and policymakers.
The Mays Cancer Center stands among the nation's leading institutions recognized for excellence in cancer care and research. It is one of only four NCI-designated Cancer Centers in Texas, offering specialized programs and delivering comprehensive, multidisciplinary care supported by clinical research.
Up to 17 million people in the US, approximately 5%, carry genetic mutations associated with cancer risk. The study highlights the importance of routine cancer screenings and suggests expanding genetic testing beyond high-risk groups.
A new Alliance trial is exploring the effectiveness of a combination of targeted therapy and immunotherapy for patients with advanced adrenocortical carcinoma, a rare and aggressive cancer. The study aims to improve disease control and quality of life for patients with limited treatment options.
Black and Asian patients were underrepresented in clinical trials, leading to worse survival outcomes compared to white counterparts, despite similar progression-free survival rates. Equitable enrollment is crucial for access to cutting-edge treatments and long-term equity in cancer care.
GemPharmatech's NeoMab platform will enable rapid and efficient discovery of fully human therapeutic antibodies against high-value targets. The collaboration aims to shorten antibody development timelines and reduce immunogenicity risks in cancer treatment.
BH3 mimetics demonstrate potent anti-cancer activity by targeting pro-survival BCL-2 proteins, effectively eradicating leukaemia cells with complex mutations. The review highlights several important findings about BH3 mimetics and their role in treating acute myeloid leukaemia.
Colorectal cancer screening modities shifted among privately insured individuals after COVID-19, with decreased colonoscopy and fecal tests, increased stool DNA tests. Differences found by sex, socioeconomic status, and metropolitan area residence.
A new study by Texas A&M University Health Science Center reveals how TFE3 oncofusions hijack RNA to build liquid-like hubs that promote cancer growth. The researchers also created a molecular switch to dissolve these hubs, cutting off tumor growth at its source.
A direct-to-patient digital health intervention increased lung cancer screening rates compared to enhanced usual care. The study's findings suggest that such interventions could improve lung cancer screening across diverse populations and healthcare settings.
Researchers discovered that folate receptor beta is widely expressed in various pediatric and adolescent solid tumors, making it a promising target for improving tumor surgery accuracy. Pafolacianine, a next-generation dye targeting folate receptors, shows promise as a tumor-agnostic imaging strategy for pediatric cancer surgery.
The ESMO Guidance on the Use of Large Language Models in Clinical Practice (ELCAP) provides a structured set of recommendations for safely adopting AI language models in oncology. The guidance emphasizes the importance of human oversight, transparent tools, and continuously monitored systems to ensure trust in AI-driven cancer care.
A recent study found that patients with advanced lung and skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine. The observation marks a significant step toward a long-awaited universal cancer vaccine to boost tumor-fighting eff...
A recent study found that cannabis may reduce opioid use among commercially insured patients with cancer diagnoses, indicating potential benefits for pain management. However, further research is needed to confirm the efficacy of cannabis as a treatment for cancer-related pain.
The study reveals geographic clusters of high and low screening for breast, cervical, and colorectal cancers in the US Northeast and Southwest. Future studies could examine county-level healthcare access to optimize cancer screening practices.
Researchers identified 5.05% of individuals carrying pathogenic variants in key cancer susceptibility genes, highlighting a significant association between these genetic variations and increased cancer risk. The study suggests that more extensive genetic screening for these genes may be warranted to identify high-risk individuals.
Mikkael Sekeres has been elected to the Executive Committee of the American Society of Hematology (ASH), a four-year term starting after the 2025 ASH Annual Meeting. He will help strengthen the organization's mission in shaping the future of hematology.
Chronic stress reprograms tumor microenvironment, fueling cancer development and metastasis through stress-activated signaling pathways. Stress management may now be part of precision oncology, suggesting potential interventions like beta-blockers and behavioral approaches.
The ESMO Congress 2025 will cover key topics including precision oncology, antibody-drug conjugates in breast cancer, dose optimisation strategies, new treatment modalities for melanoma, and immunotherapy-based approaches across various cancer settings. Promising Phase-3 studies on ADCs in bladder and lung cancer are also expected.
Researchers developed a latex-based tissue adhesive to prevent seroma formation and prolonged lymphorrhea after axillary dissection. The study found that the adhesive significantly reduced wound exudate volume and allowed patients to be discharged earlier, with no complications reported.
Ochsner Health's Genetic Wellness Assessment is an innovative screening tool that helps identify individuals at risk for hereditary cancers. The assessment evaluates personal and family history to provide personalized cancer screening and prevention plans.
Researchers found that patients with stage III or IV cancer who quit smoking lived significantly longer than those who continued smoking, with a two-fold lower rate of all-cause mortality. The study's findings emphasize the crucial role of smoking cessation support as part of standard cancer care.
Researchers found that smoking and biological sex shape how normal cells evolve in healthy bladder tissue, with certain mutations gaining an advantage to expand into clones. This study offers new insights into cancer risk and prevention by providing a way to understand tissue evolution and identify early warning signs.
The Association for Molecular Pathology has created a standardized biomarker report template to simplify complex molecular profiling data presentation to oncologists and healthcare providers. The template includes guidelines for clear formatting, therapeutic guidance, and references to clinical practice guidelines.
ACTM-838, a novel bacterial immunotherapy, enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity. The therapy shows durable anti-tumor efficacy and synergizes with anti-PD1 drugs, improving outcomes in treatment-resistant tumor models.
Paul N. Staats, MD, has been appointed Chair of the University of Maryland School of Medicine's Department of Pathology, overseeing clinical services to multiple hospitals and laboratories. He will drive partnerships and expand outpatient laboratory services.
St. Jude recognized as one of the top 10 pediatric cancer hospitals in US, consistently earning a place among the nation's best for pediatric oncology. The hospital maintains top survival rates for childhood cancers and drives progress in treatment and survivorship.
The NCCN Guidelines Navigator now covers treatment for over a dozen cancer types, including hereditary risk assessment, providing seamless navigation and search capabilities. The new format aims to improve treatment decision-making based on the latest evidence and expert-consensus.
A study of 42,451 patients found that those whose credit scores dropped after a cancer diagnosis faced a significantly higher risk of mortality. The researchers also identified high-risk demographics and socioeconomic factors associated with financial toxicity.
Researchers found that rectal bleeding increases the odds of a colorectal cancer diagnosis by 8.5 times in patients under 50, highlighting the need for symptom-driven care and lifestyle modifications to reduce the risk. The study analyzed 443 patients and identified no family history as a factor in early-onset colorectal cancers.
A topical formulation has been shown to reduce the incidence of hand-foot neuropathy in cancer patients undergoing chemotherapy, improving quality of life. The cream, developed at UMH, acts directly on neurosensory pain receptors, reducing hypersensitivity and tolerance to chemotherapy.
The WIN Symposium, featuring oncology experts, aims to accelerate the translation of research into clinical practice through keynote lectures and networking opportunities. The event is part of the Advancing Precision Medicine (APM) Annual Conference 2025.
A team led by Carnegie Mellon researchers has developed an innovative at-home urine test to detect over 30 types of early-stage solid tumors. The technology, combining synthetic biology and nucleic acid nanotechnology, aims to provide a precise and convenient way to screen for cancer.
An AI model successfully automates lymph node segmentation and extranodal extension classification from pretreatment CT scans in HPV-associated oropharyngeal carcinoma. Predicted extranodal extension is independently associated with worse oncologic outcomes, highlighting the potential for improved treatment planning.
A new study discovers a previously unknown long noncoding RNA, EUDAL, that helps oral cancer cells survive chemotherapy by permanently activating the epidermal growth factor receptor. This RNA molecule blocks the cellular tagging system, allowing EGFR to remain active and promote autophagy in cancer cells.
Researchers at Sylvester Comprehensive Cancer Center are pioneering innovative approaches to treating complex movement disorders with advanced imaging and radiosurgery techniques. The new era of functional radiosurgery enables precise treatment without invasive procedures.
A groundbreaking study enrolls 465 AYA cancer patients to test if chatbot technology and digital education tools increase uptake of genetic counseling and improve patient outcomes. The trial aims to address longstanding gaps in genetic services for AYAs aged 18-39, who often receive care with limited access to genetic specialists.
A new clinical trial report finds that stereotactic radiation therapy offers long-term survival outcomes comparable to surgery for patients with small, early-stage non-small cell lung cancer. The study included a larger patient population than previously published randomized studies and followed these patients for much longer.
A phase III trial suggests that post-operative radiation therapy can reduce cancer recurrence in patients with high-risk disease. Patients who received radiation experienced significantly fewer pelvic recurrences and improved locoregional recurrence-free survival compared to those who did not receive radiation.
A recent study suggests that the rise in early-onset cancer incidence in the US population may not be as significant as initially thought. Much of the increase is attributed to increased diagnostic scrutiny and over-diagnosis, rather than a genuine rise in clinically meaningful cancer cases.
A phase III trial comparing proton and photon radiation therapy for breast cancer found that patients report equally strong health-related quality of life with either treatment. Patients treated with protons were more likely to say they would recommend or choose it again, but overall patient-reported outcomes were similar.
A phase III trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people with locally advanced oropharyngeal cancer. Excellent tumor control and fewer long-term side effects were seen with both treatments.
A large phase III trial found that stereotactic body radiation therapy (SBRT) preserves quality of life, with fewer declines in bowel and urinary functioning. However, SBRT does not outperform standard radiation therapy for disease-free survival, with higher rates of biochemical failure and rising PSA after treatment.
A new clinical trial found that adding a PSMA-targeting agent to stereotactic radiation therapy doubled progression-free survival in patients with limited metastatic prostate cancer. The study also showed that the treatment delayed hormone therapy by 24 months and improved local control.
A new randomized study validates a predictive gene expression test that identifies patients with recurrent prostate cancer who will benefit from adding hormone therapy to radiation. The test, PAM50, groups tumors into molecular subtypes and predicts treatment outcomes.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center identify IGF2BP3 as a master switch linking cancer metabolism and RNA regulation in leukemia cells. The protein shifts energy breakdown and RNA modifications to support cell survival and multiplication.
A new study suggests that low-dose aspirin can prevent cancer in older adults based on individual characteristics. The analysis found varying treatment effects among participants, highlighting the need for personalized approaches to cancer prevention.
A study has identified KIMA, a genomic signature associated with a poor treatment response in HR+/HER2- breast cancer patients. The signature, composed of nine genes, can predict disease progression and overall survival, enabling personalized therapy selection.
A new robot-assisted bronchoscope has been shown to diagnose tiny lung tumors in hard-to-reach areas with over 84% success rate, more than three times higher than traditional methods. The technology enables accurate diagnosis in patients where conventional bronchoscopy offers no viable option.